You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百克生物(688276.SH):Ⅱ型單純皰疹病毒mRNA疫苗臨牀試驗申請獲得批准
格隆匯 12-20 15:40

格隆匯12月20日丨百克生物(688276.SH)公佈,近日收到國家藥品監督管理局下發的《藥物臨牀試驗批准通知書》,同意開展預防由Ⅱ型單純皰疹病毒感染導致的生殖器皰疹的臨牀試驗。Ⅱ型單純皰疹病毒感染而引發的生殖器皰疹,是以性行為作為主要傳播途徑的傳染病,易感染、反覆發作且無有效根治措施,已成為嚴重的公共衞生問題。為預防生殖器皰疹的發生,已有多家生物醫藥企業持續致力於單純皰疹病毒疫苗的研發工作。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account